Journal
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
Volume 31, Issue 10, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.jstrokecerebrovasdis.2022.106742
Keywords
Stroke; Stroke prevention; Milvexian; Factor XI; MRI; Randomized trial
Categories
Funding
- Bristol Myers Squibb
- Janssen Research & Development, LLC
Ask authors/readers for more resources
The study aims to evaluate the dose-response relationship of the oral medication Milvexian in patients with ischemic stroke or TIA to reduce the risk of stroke.
Background: Individuals with ischemic stroke or transient ischemic attack (TIA) have a high early risk of ischemic stroke despite dual antiplatelet therapy. The risk of ischemic stroke, and associated disability, represents a significant unmet clinical need. Genetic variants resulting in reduced factor XI levels are associated with reduced risk for ischemic stroke but are not associated with increased intracranial bleeding. Milvexian is an oral small-molecule inhibitor of FXIa that binds activated factor XI with high affinity and selectivity and may reduce the risk of stroke when added to antiplatelet drugs without significant bleeding. We aimed to evaluate the dose-response relationship of milvexian in participants treated with dual antiplatelets. Methods: We began a phase II, double-blinded, randomized, placebo-controlled trial at 367 sites in 2019. Participants (N = 2366) with ischemic stroke (National Institutes of Health Stroke Scale score <= 7) or high-risk TIA (ABCD(2) score >= 6) were randomized to 1 of 5 doses of milvexian or placebo for 90 days. Participants also received clopidogrel 75 mg daily for the first 21 days and aspirin 100 mg for 90 days. The efficacy endpoint was the composite of ischemic stroke or incident infarct on magnetic resonance imaging. Major bleeding, defined as type 3 or 5 bleeding according to the Bleeding Academic Research Consortium, was the safety endpoint. Participant follow-up will end in 2022. Conclusion: The AXIOMATIC-SSP trial will evaluate the dose-response of milvexian for ischemic stroke occurrence in participants with ischemic stroke or TIA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available